Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.05 USD | +7.27% | +2.02% | +35.65% |
Financials (USD)
Sales 2024 * | 66.97M | Sales 2025 * | 78.82M | Capitalization | 937M |
---|---|---|---|---|---|
Net income 2024 * | -152M | Net income 2025 * | -129M | EV / Sales 2024 * | 14 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 11.9 x |
P/E ratio 2024 * |
-5.62
x | P/E ratio 2025 * |
-6.91
x | Employees | 267 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.29% |
Latest transcript on Ocular Therapeutix, Inc.
1 day | +7.27% | ||
1 week | +2.02% | ||
Current month | +27.64% | ||
1 month | -24.28% | ||
3 months | -6.35% | ||
6 months | +175.00% | ||
Current year | +35.65% |
Managers | Title | Age | Since |
---|---|---|---|
Donald Notman
DFI | Director of Finance/CFO | 64 | 17-09-24 |
Chief Tech/Sci/R&D Officer | - | 21-09-27 | |
Rabia Ozden
CTO | Chief Tech/Sci/R&D Officer | 56 | 21-01-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Adrienne Graves
BRD | Director/Board Member | 69 | 23-07-09 |
Director/Board Member | 76 | 12-11-04 | |
Merilee Raines
BRD | Director/Board Member | 68 | 21-09-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 1,487 M€ | +7.21% | - | |
0.00% | 9 M€ | +9.94% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 6.05 | +7.27% | 1,987,990 |
24-05-13 | 5.64 | -0.35% | 2,314,820 |
24-05-10 | 5.66 | -3.08% | 2,175,270 |
24-05-09 | 5.84 | +1.57% | 1,718,298 |
24-05-08 | 5.75 | -3.04% | 2,676,953 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.65% | 874M | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- OCUL Stock